Skip to main content

Advertisement

Table 2 Treatment modification based on patients’ tolerance during the study in the safety analysis set

From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Treatment modification Famitinib group [cases (%)] Placebo group [cases (%)]
Treatment interruption 49 (49.5) 13 (23.6)
 Once 26 (26.3) 12 (21.8)
 Twice 8 (8.1) 1 (1.8)
 More than twice 15 (15.2) 0
Dose reduction 24 (24.2) 2 (3.6)
 One reduction 19 (19.2) 1 (1.8)
 Two reductions 5 (5.1) 1 (1.8)